Friday, August 18, 2017
 
 
Company News: Page (1) of 1 - 03/20/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
MGC Diagnostics Corporation Announces Annual Meeting of Shareholders and Fiscal 2016 Year-end Letter to Shareholders
 
(March 20, 2017)

SAINT PAUL, Minn., March 20, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced details for its upcoming Annual Meeting of Shareholders and its fiscal 2016 year-end letter to shareholders.

Annual Meeting of Shareholders
MGC Diagnostics Corporation's 2017 Annual Meeting of Shareholders will be on Wednesday, March 22, 2017, beginning at 3:30 P.M. CDT. The meeting will be held at MGC's offices located at 350 Oak Grove Parkway, Saint Paul, Minnesota 555127.

Year-end Letter to Shareholders
Please click the link to view our year-end letter to shareholders which can be found in the Business Overview 2016: http://mgcdiagnostics.com/investor-relations/annual-reports.


About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and, in the United States, France and Belgium, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2016, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contacts

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mgc-diagnostics-corporation-announces-annual-meeting-of-shareholders-and-fiscal-2016-year-end-letter-to-shareholders-300426442.html

SOURCE MGC Diagnostics Corporation

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Disease, healthcare, Technology, Surgery, Science, Medical Technology, Medical, Business, Other,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • HeadAid Products Soon to be Available on Go4ItNutrition.com
  • Ascension Teams with Plug and Play Tech Center to Connect with Health and Wellness Startups
  • Global Sleep Apnea Devices Market to Grow at a CAGR of 7.8% by 2024 - Large Scale Benefits of Medical Devices is Driving Demand for Medical Platforms.
  • At 8+% CAGR Lateral Flow Assay Market Potentially Worth $8.24 Billion by 2022 Led by Asia-Pacific Region
  • UNITY Biotechnology Announces Extension of Series B Financing Bringing Total Round to $151 Million

    Cancer
  • argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017
  • Three Grant Funding Opportunities for Brain Tumor Research Funding Open Today
  • Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results
  • ASPCA and the Petco Foundation Partner to Grant $1.5 Million to Dogs Playing For Life to Expand Life-Saving Playgroups Nationwide
  • United States Pain Management Therapeutics Market, Patients Volume, and 50 Companys Pipeline Analysis (By Product, Indication, Phase of Development)
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines